Patent intelligence · US
US 11566263
Compositions and methods for treating CEP290 associated disease
Compositions and methods for treating CEP290 associated disease
Patent details — US 11566263
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 31, 2023
- Expiration
- Jan 26, 2043
- Applicant
- Editas Medicine, Inc.
- Claims
- 28
- CPC classes
- A61K, A61K35/761, A61K9/0048
Quick answer
US 11566263 (Compositions and methods for treating CEP290 associated disease) is held by Editas Medicine, Inc.. Status: granted. Granted Jan 31, 2023. Expires Jan 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Editas Medicine, Inc.
- Grant date
- Expiration
- Claims
- 28
- CPC classes
- A61K, A61K35/761, A61K9/0048
More from Editas Medicine, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12359223
Systems and methods for modulating chromosomal rearrangements
granted -
US 12331328
CRISPR/Cas9-mediated exon-skipping approach for USH2A-associated usher syndrome
granted -
US 12325854
Crispr-CPF1-related methods, compositions and components for cancer immunotherapy
granted -
US 12201699
Compositions and methods for promoting homology directed repair
granted -
US 12031132
Systems and methods for the treatment of hemoglobinopathies
granted -
US 11963982
CRISPR/RNA-guided nuclease systems and methods
granted -
US 11952408
HPV-specific binding molecules
granted -
US 11911415
CRISPR/Cas-related methods and compositions for improving transplantation
granted
Frequently asked questions
What is US patent 11566263?
US 11566263 (Compositions and methods for treating CEP290 associated disease) is held by Editas Medicine, Inc.. Status: granted. Granted Jan 31, 2023. Expires Jan 26, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11566263?
Editas Medicine, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 21 pharmaceutical patents for this assignee.
When does US 11566263 expire?
Our index shows an expiration date of Jan 26, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.